Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel discussion. A question and answer session will follow the presentations.
达布林,2024年9月25日/ PRNewswire/ -- 阿尔凯默斯plc(纳斯达克:ALKS)宣布,将于2024年10月9日星期三上午10:00在马萨诸塞州沃尔瑟姆举办投资者活动,面向财务分析师和机构投资者。阿尔凯默斯研发团队成员将审查公司的奥雷欣组合和发展策略。活动还将包括医师和思想领袖小组讨论。演讲结束后将有问答环节。
The event will also be available virtually via webcast. Registration for the webcast is available on the Investors section of the company's website at . To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start. A replay of the webcast will be archived on the Investors section of the company's website at for 30 days following the presentation.
该活动也将通过网络直播提供虚拟参与。用户可以在公司网站的投资者部分注册网络直播。为了确保及时连接,建议用户至少提前15分钟注册。网络直播的重播将存档在公司网站的投资者部分,持续30天。
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at .
关于阿尔凯默斯公
阿尔凯默斯是一家全球性的生物制药公司,致力于开发神经科学领域的创新药物。该公司拥有一系列专有的商业产品,用于治疗酒精依赖、阿片类药物依赖、精神分裂症和I型双相情感障碍,并拥有一系列正在发展中的用于神经系统疾病,包括嗜睡病的临床和临床前候选药。总部位于爱尔兰的阿尔凯默斯还设有美国马萨诸塞州的企业办公室和研发中心以及俄亥俄州的制造设施。欲了解更多信息,请访问阿尔凯默斯公司的网站.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
阿尔凯默斯联系人:
杰米·康斯坦丁
投资者关系
+1 781 873 2402
SOURCE Alkermes plc
资料来源:阿尔凯默斯。